Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Financial Toxicity and Time Toxicity in Multiple Myeloma: Prevalence, Predictors, and Impact on QOL

Rahul Banerjee, Andrew J. Cowan, Marivel Chavez-Ortega, Paul A Carpenter, Masumi Ueda Oshima, Rachel B. Salit, Phuong T Vo, Catherine J. Lee, Rohtesh S. Mehta, Nicole M. Kuderer, Veena Shankaran, Stephanie J. Lee, Christopher T. Su

Blood (2023) 142 (Supplement 1): 2386.

https://doi.org/10.1182/blood-2023-174554

Published: 2023

Journal Articles

Intensity of End of Life Care for Hematologic Malignancy Patients in Western Washington, United States and Alberta, Canada

Ali Raza Khaki, MD, Yuan Xu, PhD, Shasank R Chennupati, PharmD, MPH, Scott D Ramsey, MD PhD, Catherine Fedorenko, MMSci, Veena Shankaran, MD, Andrew J. Cowan, MD, Winson Y Cheung, MDMPH

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-134825

Published: 2020

Journal Articles

Comparison of Outcomes and Utilization of Therapy in Multiple Myeloma Patients in the USA and Alberta, Canada

Andrew J. Cowan, MD, Shasank R Chennupati, PharmD, MPH, Yuan Xu, PhD, Ang Li, MDMS, David A. Garcia, MD, Edward Libby, MD, Catherine Fedorenko, MMSci, Scott D Ramsey, MD PhD, Veena Shankaran, MD, Winson Y Cheung, MDMPH

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-141088

Published: 2020

Journal Articles

A Predictive Cost-Effectiveness Analysis of the Treatment of Chronic, Refractory Immune Thrombocytopenic Purpura (ITP) with Novel Agents: An Economic Model Based on Long-Term Treatment Data with Rituximab Versus Romiplostim.

Wendy Oatis, MD, JD, Veena Shankaran, MD, Faisal Saghir, MD, Charles L. Bennett, MD, PhD, MPP, Elizabeth Richey, BA, James B Bussel

Blood (2008) 112 (11): 3433.

https://doi.org/10.1182/blood.V112.11.3433.3433

Published: 2008

Journal Articles

“Getting to go” for FDA Approvals for the Treatment of Hematologic Versus Solid Tumor Malignancies: A Report from the Research on Adverse Drug Events and Reports (RADAR) Project

Elizabeth A Richey, BA, Veena Shankaran, MD, Steven Hirschfeld, MD, PhD, Steven M Trifilio, RPh, June McKoy, MD, MPH, Kenneth R Carson, MD, Beatrice J Edwards, MD, FACP, Thanh Ha Luu, BA, Narissa Nonzee, BS, A. Oliver Sartor, MD, Charles L. Bennett, MD, PhD, MPP

Blood (2008) 112 (11): 2402.

https://doi.org/10.1182/blood.V112.11.2402.2402

Published: 2008

Journal Articles

Waiting for Godot: Thirty-Six Month Follow-Up on Accelerated FDA Approval of Drugs To Treat Hematologic Malignancies.

Veena Shankaran, MD, June McKoy, MD, MPH, JD, Ben Djulbegovic, MD, PhD, Allison Lyons, BA, Ken Carson, MD, Cara Tigue, BA, Neal Dandade, BA, Martin Tallman, MD, Oliver Sartor, MD, Charles Bennett, MD, PhD, MPP

Blood (2007) 110 (11): 3340.

https://doi.org/10.1182/blood.V110.11.3340.3340

Published: 2007

NARROW

Financial Toxicity and Time Toxicity in Multiple Myeloma: Prevalence, Predictors, and Impact on QOL

Intensity of End of Life Care for Hematologic Malignancy Patients in Western Washington, United States and Alberta, Canada

Comparison of Outcomes and Utilization of Therapy in Multiple Myeloma Patients in the USA and Alberta, Canada

A Predictive Cost-Effectiveness Analysis of the Treatment of Chronic, Refractory Immune Thrombocytopenic Purpura (ITP) with Novel Agents: An Economic Model Based on Long-Term Treatment Data with Rituximab Versus Romiplostim.

“Getting to go” for FDA Approvals for the Treatment of Hematologic Versus Solid Tumor Malignancies: A Report from the Research on Adverse Drug Events and Reports (RADAR) Project

Waiting for Godot: Thirty-Six Month Follow-Up on Accelerated FDA Approval of Drugs To Treat Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Financial Toxicity and Time Toxicity in Multiple Myeloma: Prevalence, Predictors, and Impact on QOL

Intensity of End of Life Care for Hematologic Malignancy Patients in Western Washington, United States and Alberta, Canada

Comparison of Outcomes and Utilization of Therapy in Multiple Myeloma Patients in the USA and Alberta, Canada

A Predictive Cost-Effectiveness Analysis of the Treatment of Chronic, Refractory Immune Thrombocytopenic Purpura (ITP) with Novel Agents: An Economic Model Based on Long-Term Treatment Data with Rituximab Versus Romiplostim.

“Getting to go” for FDA Approvals for the Treatment of Hematologic Versus Solid Tumor Malignancies: A Report from the Research on Adverse Drug Events and Reports (RADAR) Project

Waiting for Godot: Thirty-Six Month Follow-Up on Accelerated FDA Approval of Drugs To Treat Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only